Senseonics Announces Aetna’s Positive Coverage Decision for Eversense
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization
of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that Aetna, the
third largest commercial health plan provider in the United States, is providing coverage for Eversense, effective immediately.
Aetna’s plan provides coverage for approximately 22 million lives in the United States. This recent coverage decision adds to
the growing body of payers processing claims and paying for Eversense in the U.S.
“We are pleased that one of the largest national payers in the U.S. is now covering Eversense, and that Aetna recognizes the
value of CGM and the value Eversense can bring to the market in terms of patient adherence,” said Tim Goodnow, President and Chief
Executive Officer of Senseonics. “We believe this coverage decision represents a major milestone and has the potential to
facilitate broad patient and physician access to Eversense in the U.S.”
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The
sensor insertion and removal is performed by a physician. The Eversense CGM System is a prescription device? patients should talk
to their doctor to learn more. For important safety information, see
https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of
transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its
inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The
Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States.
The Eversense® CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe. For more information
on Senseonics, please visit
www.senseonics.com.
INVESTOR CONTACT
Senseonics Holdings, Inc.
R. Don Elsey, 301-556-1602
Chief Financial Officer
don.elsey@senseonics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005926/en/